WEC
IMDX

Winslow Evans & Crocker’s Insight Molecular Diagnostics IMDX Stock Holding History

Winslow Evans & Crocker’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$6K Hold
135
– – ﹤0.01% 1055
2020
Q3 		$4K Buy
+135
New +$3.87K ﹤0.01% 916

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Winslow Evans & Crocker's IMDX Position: Q4 2020 in Review

Winslow Evans & Crocker held its Insight Molecular Diagnostics (IMDX) position steady in Q4 2020 at 135 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1055.

Winslow Evans & Crocker first reported a position in IMDX in Q3 2020 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold IMDX as of Q4 2020.

  • Winslow Evans & Crocker held 135 shares of Insight Molecular Diagnostics worth $6K as of Q4 2020.
  • Winslow Evans & Crocker left its Insight Molecular Diagnostics share count unchanged in Q4 2020.
  • Insight Molecular Diagnostics made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1055 holding.
  • Winslow Evans & Crocker first reported a position in Insight Molecular Diagnostics in Q3 2020 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.